Avant Diagnostics, Inc. (AVDX) Leads Development i
Post# of 104
Posted On: 10/15/2015 5:45:09 PM
Avant Diagnostics, Inc. (AVDX) Leads Development in Early Ovarian Cancer Detection Technology
Great strides in medical technology are being undertaken by Avant Diagnostics, a company that focuses its developments on the human genome project, which aims to map out the entire DNA sequence of a human. Innovations in this endeavor may treat, prevent, and cure disease as scientists will have a blueprint of how humans have developed over time along with what genes lead to illness. The company hopes to develop genetic research that can detect illness early in individuals so that treatment can avert progression or death.
With this goal in mind, Avant Diagnostics has developed the first large panel biomarker screening test for ovarian cancer. This test, OvaDx®, measures the activation of immune systems in blood samples in response to early stage ovarian tumor cell development. The test has high sensitivity to readings at 79.7% and can identify stage I, II, III, and IV Ovarian cancer with great accuracy. With ~80% sensitivity, IA disease can also be detected.
According to the American Cancer Society, 21,290 women will be diagnosed and 14,180 will die from ovarian cancer this year. A woman’s risk of getting the cancer is 1 in 75, making early detection technology essential. Currently, the three leading detection processes are the pelvic exam, transvaginal ultrasound, and CA-125 blood test. However, each of these tests lack accuracy and do not necessarily lower the cancer’s death rate.
The company is currently underway in testing previously acquired ovarian cancer specimens that will serve as a validation study for the pre-Submission package to be submitted to the Food and Drug Administration (FDA) for review. Then a trial for OvaDx® 510(k) can begin. The company needs to get the FDA’s approval for the product before selling. This microarray-based test will be offered to women for overall health checkups and to those who have a predisposed risk to the cancer.
Avant Diagnostics intends to develop advanced early detection technologies that will then lead to developments in surgical options and therapies for patients. Furthermore, if OvaDx® gains FDA approval, women will have another, more accurate, option for ovarian cancer detection.
For more information, please visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Great strides in medical technology are being undertaken by Avant Diagnostics, a company that focuses its developments on the human genome project, which aims to map out the entire DNA sequence of a human. Innovations in this endeavor may treat, prevent, and cure disease as scientists will have a blueprint of how humans have developed over time along with what genes lead to illness. The company hopes to develop genetic research that can detect illness early in individuals so that treatment can avert progression or death.
With this goal in mind, Avant Diagnostics has developed the first large panel biomarker screening test for ovarian cancer. This test, OvaDx®, measures the activation of immune systems in blood samples in response to early stage ovarian tumor cell development. The test has high sensitivity to readings at 79.7% and can identify stage I, II, III, and IV Ovarian cancer with great accuracy. With ~80% sensitivity, IA disease can also be detected.
According to the American Cancer Society, 21,290 women will be diagnosed and 14,180 will die from ovarian cancer this year. A woman’s risk of getting the cancer is 1 in 75, making early detection technology essential. Currently, the three leading detection processes are the pelvic exam, transvaginal ultrasound, and CA-125 blood test. However, each of these tests lack accuracy and do not necessarily lower the cancer’s death rate.
The company is currently underway in testing previously acquired ovarian cancer specimens that will serve as a validation study for the pre-Submission package to be submitted to the Food and Drug Administration (FDA) for review. Then a trial for OvaDx® 510(k) can begin. The company needs to get the FDA’s approval for the product before selling. This microarray-based test will be offered to women for overall health checkups and to those who have a predisposed risk to the cancer.
Avant Diagnostics intends to develop advanced early detection technologies that will then lead to developments in surgical options and therapies for patients. Furthermore, if OvaDx® gains FDA approval, women will have another, more accurate, option for ovarian cancer detection.
For more information, please visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Avant Diagnostics, Inc. (AVDX) Stock Research Links
Scroll down for more posts ▼